Skip to main content
Top
Published in: World Journal of Surgery 3/2011

01-03-2011

Trends in the Surgical Treatment of Ulcerative Colitis over Time: Increased Mortality and Centralization of Care

Authors: Michelle C. Ellis, Brian S. Diggs, John T. Vetto, Daniel O. Herzig

Published in: World Journal of Surgery | Issue 3/2011

Login to get access

Abstract

Background

New medical therapies available to ulcerative colitis (UC) patients have influenced operative mortality for patients requiring colectomy. We sought to examine trends in treatment and outcome for UC patients treated surgically.

Methods

A review of 36,447 UC patients from the Nationwide Inpatient Sample was performed, comparing the pre-monoclonal antibody era (1990–1996) to the present-day era (2000–2006). Patients treated with total colectomy with ileostomy or proctocolectomy with ileal pouch were reviewed for outcome measures and practice setting (rural, urban non-teaching, urban teaching). Our main outcome measures were in-hospital mortality, length of stay, and total charges.

Results

Total colectomy (n = 30,362) was performed five times more often than proctocolectomy (n = 6,085). When comparing the two study periods, mortality after total colectomy increased 3.8% to 4.6% (p = 0.0003). This difference was primarily due to increasing mortality in later years; when 1995–1996 was compared to 2005–2006, mortality increased from 3.6% to 5.6% (p < 0.0001). There were no deaths in the proctocolectomy group (p < 0.0001). The distribution by practice setting shifted over the two study periods, decreasing in rural (7.0% to 4.8%) and urban non-teaching (43.7% to 28.4%) centers, and increasing in urban teaching centers (49.3% to 66.8%). The total inflation-adjusted charges per patient increased significantly ($34,638 vs. $43,621; p < 0.0001).

Conclusions

The mortality rate after total colectomy is increasing, and the difference is accentuated in the years since widespread use of monoclonal antibody therapy. The care of these patients is being shifted to urban teaching centers and is becoming more expensive.
Literature
1.
go back to reference Langholz E, Munkholm P, Davidsen M et al (1994) Course of ulcerative colitis: analysis of changes in disease activity over years. Gastroenterology 107:3–11PubMed Langholz E, Munkholm P, Davidsen M et al (1994) Course of ulcerative colitis: analysis of changes in disease activity over years. Gastroenterology 107:3–11PubMed
2.
go back to reference Kunitake H, Hodin R, Shellito PC et al (2008) Perioperative treatment with infliximab in patients with Crohn’s disease and ulcerative colitis is not associated with an increased rate of postoperative complications. J Gastrointest Surg 12:1730–1736 (discussion 1736–1737)CrossRefPubMed Kunitake H, Hodin R, Shellito PC et al (2008) Perioperative treatment with infliximab in patients with Crohn’s disease and ulcerative colitis is not associated with an increased rate of postoperative complications. J Gastrointest Surg 12:1730–1736 (discussion 1736–1737)CrossRefPubMed
3.
go back to reference Lawson MM, Thomas AG, Akobeng AK (2006) Tumour necrosis factor alpha blocking agents for induction of remission in ulcerative colitis. Cochrane Database Syst Rev. 2006 Jul 19(3):CD005112 Lawson MM, Thomas AG, Akobeng AK (2006) Tumour necrosis factor alpha blocking agents for induction of remission in ulcerative colitis. Cochrane Database Syst Rev. 2006 Jul 19(3):CD005112
4.
go back to reference Russo EA, Harris AW, Campbell S et al (2009) Experience of maintenance infliximab therapy for refractory ulcerative colitis from six centres in England. Aliment Pharmacol Ther 29:308–314CrossRefPubMed Russo EA, Harris AW, Campbell S et al (2009) Experience of maintenance infliximab therapy for refractory ulcerative colitis from six centres in England. Aliment Pharmacol Ther 29:308–314CrossRefPubMed
5.
go back to reference Schluender SJ, Ippoliti A, Dubinsky M et al (2007) Does infliximab influence surgical morbidity of ileal pouch-anal anastomosis in patients with ulcerative colitis? Dis Colon Rectum 50:1747–1753CrossRefPubMed Schluender SJ, Ippoliti A, Dubinsky M et al (2007) Does infliximab influence surgical morbidity of ileal pouch-anal anastomosis in patients with ulcerative colitis? Dis Colon Rectum 50:1747–1753CrossRefPubMed
6.
go back to reference Selvasekar CR, Cima RR, Larson DW et al (2007) Effect of infliximab on short-term complications in patients undergoing operation for chronic ulcerative colitis. J Am Coll Surg 204:956–962 (discussion 962–963)CrossRefPubMed Selvasekar CR, Cima RR, Larson DW et al (2007) Effect of infliximab on short-term complications in patients undergoing operation for chronic ulcerative colitis. J Am Coll Surg 204:956–962 (discussion 962–963)CrossRefPubMed
7.
go back to reference Jarnerot G, Hertervig E, Friis-Liby I et al (2005) Infliximab as rescue therapy in severe to moderately severe ulcerative colitis: a randomized, placebo-controlled study. Gastroenterology 128:1805–1811CrossRefPubMed Jarnerot G, Hertervig E, Friis-Liby I et al (2005) Infliximab as rescue therapy in severe to moderately severe ulcerative colitis: a randomized, placebo-controlled study. Gastroenterology 128:1805–1811CrossRefPubMed
8.
go back to reference Sandborn WJ, Rutgeerts P, Feagan BG et al (2009) Colectomy rate comparison after treatment of ulcerative colitis with placebo or infliximab. Gastroenterology 137:1250–1260 quiz 1520CrossRefPubMed Sandborn WJ, Rutgeerts P, Feagan BG et al (2009) Colectomy rate comparison after treatment of ulcerative colitis with placebo or infliximab. Gastroenterology 137:1250–1260 quiz 1520CrossRefPubMed
9.
go back to reference Aratari A, Papi C, Clemente V et al (2008) Colectomy rate in acute severe ulcerative colitis in the infliximab era. Dig Liver Dis 40:821–826CrossRefPubMed Aratari A, Papi C, Clemente V et al (2008) Colectomy rate in acute severe ulcerative colitis in the infliximab era. Dig Liver Dis 40:821–826CrossRefPubMed
10.
go back to reference Bressler B, Law JK, Al Nahdi Sheraisher N et al (2008) The use of infliximab for treatment of hospitalized patients with acute severe ulcerative colitis. Can J Gastroenterol 22:937–940PubMed Bressler B, Law JK, Al Nahdi Sheraisher N et al (2008) The use of infliximab for treatment of hospitalized patients with acute severe ulcerative colitis. Can J Gastroenterol 22:937–940PubMed
11.
go back to reference Mor IJ, Vogel JD, da Luz Moreira A et al (2008) Infliximab in ulcerative colitis is associated with an increased risk of postoperative complications after restorative proctocolectomy. Dis Colon Rectum 51:1202–1207 discussion 1207–1210CrossRefPubMed Mor IJ, Vogel JD, da Luz Moreira A et al (2008) Infliximab in ulcerative colitis is associated with an increased risk of postoperative complications after restorative proctocolectomy. Dis Colon Rectum 51:1202–1207 discussion 1207–1210CrossRefPubMed
12.
go back to reference Bordeianou L, Kunitake H, Shellito P et al (2009) Preoperative infliximab treatment in patients with ulcerative and indeterminate colitis does not increase rate of conversion to emergent and multistep abdominal surgery. Int J Colorectal Dis 25:401–404CrossRefPubMed Bordeianou L, Kunitake H, Shellito P et al (2009) Preoperative infliximab treatment in patients with ulcerative and indeterminate colitis does not increase rate of conversion to emergent and multistep abdominal surgery. Int J Colorectal Dis 25:401–404CrossRefPubMed
13.
go back to reference Longobardi T, Bernstein CN (2007) Utilization of health-care resources by patients with IBD in Manitoba: a profile of time since diagnosis. Am J Gastroenterol 102:1683–1691CrossRefPubMed Longobardi T, Bernstein CN (2007) Utilization of health-care resources by patients with IBD in Manitoba: a profile of time since diagnosis. Am J Gastroenterol 102:1683–1691CrossRefPubMed
14.
go back to reference Bewtra M, Su C, Lewis JD (2007) Trends in hospitalization rates for inflammatory bowel disease in the united states. Clin Gastroenterol Hepatol 5:597–601CrossRefPubMed Bewtra M, Su C, Lewis JD (2007) Trends in hospitalization rates for inflammatory bowel disease in the united states. Clin Gastroenterol Hepatol 5:597–601CrossRefPubMed
15.
go back to reference Nguyen GC, Tuskey A, Dassopoulos T et al (2007) Rising hospitalization rates for inflammatory bowel disease in the United States between 1998 and 2004. Inflamm Bowel Dis 13:1529–1535CrossRefPubMed Nguyen GC, Tuskey A, Dassopoulos T et al (2007) Rising hospitalization rates for inflammatory bowel disease in the United States between 1998 and 2004. Inflamm Bowel Dis 13:1529–1535CrossRefPubMed
16.
go back to reference Bernstein CN, Nabalamba A (2006) Hospitalization, surgery, and readmission rates of IBD in Canada: a population-based study. Am J Gastroenterol 101:110–118CrossRefPubMed Bernstein CN, Nabalamba A (2006) Hospitalization, surgery, and readmission rates of IBD in Canada: a population-based study. Am J Gastroenterol 101:110–118CrossRefPubMed
17.
go back to reference Cannom RR, Kaiser AM, Ault GT et al (2009) Inflammatory bowel disease in the United States from 1998 to 2005: has infliximab affected surgical rates? Am Surg 75:976–980PubMed Cannom RR, Kaiser AM, Ault GT et al (2009) Inflammatory bowel disease in the United States from 1998 to 2005: has infliximab affected surgical rates? Am Surg 75:976–980PubMed
Metadata
Title
Trends in the Surgical Treatment of Ulcerative Colitis over Time: Increased Mortality and Centralization of Care
Authors
Michelle C. Ellis
Brian S. Diggs
John T. Vetto
Daniel O. Herzig
Publication date
01-03-2011
Publisher
Springer-Verlag
Published in
World Journal of Surgery / Issue 3/2011
Print ISSN: 0364-2313
Electronic ISSN: 1432-2323
DOI
https://doi.org/10.1007/s00268-010-0910-9

Other articles of this Issue 3/2011

World Journal of Surgery 3/2011 Go to the issue